Skye Bioscience (SKYE) Competitors $3.02 -0.23 (-7.08%) (As of 03:58 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SKYE vs. CYRX, NGNE, BTMD, DSGN, VYGR, CTNM, PROC, SLRN, KMDA, and CGCShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Cryoport (CYRX), Neurogene (NGNE), biote (BTMD), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Procaps Group (PROC), Acelyrin (SLRN), Kamada (KMDA), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. Cryoport Neurogene biote Design Therapeutics Voyager Therapeutics Contineum Therapeutics Procaps Group Acelyrin Kamada Canopy Growth Skye Bioscience (NASDAQ:SKYE) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Does the MarketBeat Community favor SKYE or CYRX? Cryoport received 230 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 64.96% of users gave Cryoport an outperform vote. CompanyUnderperformOutperformSkye BioscienceOutperform Votes11100.00% Underperform VotesNo VotesCryoportOutperform Votes24164.96% Underperform Votes13035.04% Do analysts rate SKYE or CYRX? Skye Bioscience currently has a consensus target price of $18.67, indicating a potential upside of 474.36%. Cryoport has a consensus target price of $12.50, indicating a potential upside of 54.51%. Given Skye Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Skye Bioscience is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Cryoport 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is SKYE or CYRX more profitable? Skye Bioscience has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -45.78% -37.44% Cryoport -70.08%-13.35%-6.43% Do insiders & institutionals believe in SKYE or CYRX? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 92.9% of Cryoport shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by insiders. Comparatively, 10.1% of Cryoport shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer SKYE or CYRX? In the previous week, Skye Bioscience had 2 more articles in the media than Cryoport. MarketBeat recorded 3 mentions for Skye Bioscience and 1 mentions for Cryoport. Cryoport's average media sentiment score of 1.67 beat Skye Bioscience's score of 1.38 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher earnings and valuation, SKYE or CYRX? Skye Bioscience has higher earnings, but lower revenue than Cryoport. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$37.65MN/AN/ACryoport$226.11M1.77-$99.59M-$3.38-2.39 Which has more volatility and risk, SKYE or CYRX? Skye Bioscience has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. SummarySkye Bioscience beats Cryoport on 8 of the 15 factors compared between the two stocks. Ad Jack Carter Trading"X-Ray Vision" could find thousands of hidden market opportunitiesLet me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.Just tap here to join the presentation. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.61M$6.84B$5.13B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E RatioN/A10.77135.2417.51Price / SalesN/A283.871,174.53134.92Price / CashN/A56.6540.4837.95Price / Book-19.125.384.884.94Net Income-$37.65M$151.62M$118.56M$225.30M7 Day Performance-10.22%-4.82%14.97%-1.11%1 Month Performance-28.73%2.04%15.07%7.29%1 Year Performance5.43%16.11%34.31%23.06% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience2.1057 of 5 stars$3.02-7.1%$18.67+518.1%+15.1%$91.63MN/A0.0011Positive NewsCYRXCryoport3.2288 of 5 stars$7.55-1.8%$12.50+65.6%-48.9%$373.20M$226.11M-2.321,170Short Interest ↓Positive NewsNGNENeurogene3.9667 of 5 stars$24.42+3.9%$60.83+149.1%N/A$362.76M$925,000.000.0090BTMDbiote3.4078 of 5 stars$6.60+3.6%$9.11+38.0%+24.5%$358.62M$193.06M24.77194Analyst ForecastNews CoveragePositive NewsGap UpDSGNDesign Therapeutics0.3707 of 5 stars$6.29+12.3%$7.00+11.3%+144.1%$356.15MN/A-7.1840Positive NewsVYGRVoyager Therapeutics4.6442 of 5 stars$6.49+3.5%$17.00+161.9%-21.7%$354.55M$250.01M8.83100CTNMContineum Therapeutics2.0757 of 5 stars$13.52-3.6%$29.25+116.3%N/A$348.55M$50M0.0031PROCProcaps Group0.7671 of 5 stars$3.08+27.8%N/A+19.8%$347.49M$414.10M5.105,500News CoverageGap DownHigh Trading VolumeSLRNAcelyrin2.8717 of 5 stars$3.37+4.3%$11.75+248.7%-55.6%$338.11MN/A-1.31135KMDAKamada4.1934 of 5 stars$5.85-0.3%$14.50+147.9%-3.0%$336.26M$158.38M20.96360News CoveragePositive NewsCGCCanopy Growth2.4246 of 5 stars$3.05-1.9%$3.50+14.8%-41.2%$332.27M$220.27M-0.631,029Analyst DowngradeShort Interest ↓News Coverage Related Companies and Tools Related Companies CYRX Alternatives NGNE Alternatives BTMD Alternatives DSGN Alternatives VYGR Alternatives CTNM Alternatives PROC Alternatives SLRN Alternatives KMDA Alternatives CGC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SKYE) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectCrypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
